Skip to main content
. 2022 May 31;37(23):e180. doi: 10.3346/jkms.2022.37.e180

Table 1. Summary of immunogenicity of COVID-19 vaccination between healthy people and patients with end-stage renal disease.

Variables Healthy people, two doses of ChAdOx1 ESRD patients, ChAdOx1-BNT162b2 P valuea ESRD patients, two doses of ChAdOx1 P valueb
SARS-CoV-2 binding antibody titer measured by Elecsys® Anti-SARS-CoV-2 S, AU/mL
Day 0, from 1st dose 0.4 ± 0.0 0.4 ± 0.0 1.000 0.4 ± 0.0 1.000
Day 14, from 1st dose 6.4 ± 13.2 0.8 ± 1.5 < 0.001 0.5 ± 0.2 0.003
Day 28, from 1st dose 62.3 ± 60.3 15.0 ± 28.8 < 0.001 23.3 ± 46.9 0.020
Day 56, from 1st dose 69.0 ± 53.3 27.1 ± 39.0 < 0.001 39.7 ± 69.3 0.030
Day 7, from 2nd dose 1,192.0 ± 881.7 3,028.3 ± 2,687.2 0.004 523.9 ± 672.9 0.042
Day 50, from 2nd dose 1,149.9 ± 1,493.4 2,373.9 ± 1,075.9 < 0.001 891.9 ± 1,256.8 0.229
SARS-CoV-2 neutralizing antibody activity measured by cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, % inhibition
Day 0, from 1st dose 10.1 ± 10.4 4.5 ± 4.6 0.116 9.5 ± 5.1 0.697
Day 14, from 1st dose 24.7 ± 18.5 14.0 ± 9.1 0.016 6.5 ± 10.2 0.024
Day 28, from 1st dose 50.4 ± 21.2 20.4 ± 16.6 < 0.001 20.7 ± 19.4 0.010
Day 56, from 1st dose 42.5 ± 18.5 17.7 ± 18.4 < 0.001 27.7 ± 25.4 0.096
Day 7, from 2nd dose 74.8 ± 20.3 86.7 ± 18.2 < 0.001 61.4 ± 29.4 0.291
Day 50, from 2nd dose 77.0 ± 17.6 91.7 ± 14.4 < 0.001 74.8 ± 26.1 0.832
SARS-CoV-2 neutralizing antibody activity measured by R-FIND SARS-CoV-2 Neutralizing Antibody ELISA, % inhibition
Day 0, from 1st dose 0.3 ± 6.4 −7.2 ± 4.3 < 0.001 −6.2 ± 4.3 0.015
Day 14, from 1st dose 27.2 ± 20.8 −3.9 ± 9.2 < 0.001 −5.6 ± 7.4 0.001
Day 28, from 1st dose 45.4 ± 25.7 14.2 ± 20.7 < 0.001 23.7 ± 22.6 0.063
Day 56, from 1st dose 45.7 ± 22.0 14.4 ± 22.1 < 0.001 26.5 ± 22.1 0.055
Day 7, from 2nd dose 86.3 ± 13.5 87.8 ± 18.2 0.210 64.5 ± 27.4 0.030
Day 50, from 2nd dose 84.6 ± 14.2 93.4 ± 5.5 0.002 76.1 ± 28.6 0.485
Proportion of positive result of SARS-CoV-2 binding antibody measured by Elecsys® Anti-SARS-CoV-2 S
Day 0, from 1st dose 0 0 0
Day 14, from 1st dose 38 (69) 3 (12) < 0.001 1 (17) 0.020
Day 28, from 1st dose 54 (98) 18 (72) < 0.001 4 (67) 0.024
Day 56, from 1st dose 55 (100) 23 (92) 0.106 6 (100)
Day 7, from 2nd dose 55 (100) 25 (100) 6 (100)
Day 50, from 2nd dose 55 (100) 25 (100) 6 (100)
Proportion of positive result of SARS-CoV-2 neutralizing antibody activity measured by cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit
Day 0, from 1st dose 1 (2) 0 1.000 0 1.000
Day 14, from 1st dose 21 (38) 1 (4) < 0.001 0 0.085
Day 28, from 1st dose 44 (80) 5 (20) < 0.001 1 (17) 0.004
Day 56, from 1st dose 41 (75) 5 (20) < 0.001 3 (50) 0.335
Day 7, from 2nd dose 54 (98) 25 (100) 1.000 5 (83) 0.189
Day 50, from 2nd dose 55 (100) 24 (96) 0.313 5 (83) 0.098
Proportion of positive result of SARS-CoV-2 neutralizing antibody activity measured by R-FIND SARS-CoV-2 Neutralizing Antibody ELISA
Day 0, from 1st dose 0 0 0
Day 14, from 1st dose 26 (47) 1 (4) < 0.001 0 0.033
Day 28, from 1st dose 42 (76) 5 (20) < 0.001 3 (50) 0.179
Day 56, from 1st dose 45 (82) 5 (20) < 0.001 2 (33) 0.021
Day 7, from 2nd dose 55 (100) 25 (100) 5 (83) 0.098
Day 50, from 2nd dose 55 (100) 25 (100) 5 (83) 0.098

Results are expressed as mean ± standard deviation or frequencies (and proportions).

COVID-19 = coronavirus disease 2019, ESRD = end-stage renal disease, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, ELISA = enzyme-linked immunosorbent assay.

aComparison between Healthy people, two doses of ChAdOx1 and ESRD patients, ChAdOx1-BNT162b2.

bComparison between Healthy people, two doses of ChAdOx1and ESRD patients, two doses of ChAdOx1.